Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 96 publications
Talquetamab-Daratumumab in Relapsed or Refractory Myeloma.
Journal: The New England journal of medicine
Published: June 15, 2026
Teclistamab in Multiple Myeloma with One to Three Previous Lines of Therapy.
Journal: The New England journal of medicine
Published: May 29, 2026
Clinical and Biological Implications of TP53 Abnormalities in Relapsed/Refractory Multiple Myeloma: The DEDALO Study.
Journal: Clinical lymphoma, myeloma & leukemia
Published: April 27, 2026
Salvage treatment patterns in multiple myeloma patients progressing after lenalidomide maintenance: A real-life study from European Myeloma Network (EMN) Italy.
Journal: British journal of haematology
Published: April 26, 2026
Belantamab Mafodotin for Patients With Multiple Myeloma: Clinical Development and Practical Strategies for Dose Optimization and Toxicity Management.
Journal: Clinical lymphoma, myeloma & leukemia
Published: April 07, 2026
Indirect treatment comparison of DVRd plus DR maintenance (PERSEUS study) versus DVTd or VTd with or without lenalidomide maintenance in transplant-eligible patients with previously untreated multiple myeloma.
Journal: Journal of medical economics
Published: February 17, 2026
The Evolution of Chimeric Antigen Receptor T-Cell, Bispecific Antibodies and Antibody-Drug Conjugates for the Treatment of Multiple Myeloma.
Journal: Clinical lymphoma, myeloma & leukemia
Published: February 06, 2026
Teclistamab plus Daratumumab in Relapsed or Refractory Multiple Myeloma.
Journal: The New England journal of medicine
Published: December 09, 2025
Undetectable Minimal Residual Disease in Multiple Myeloma: Bridging the Gap Between Clinical Trials and Real-life Application.
Journal: Clinical lymphoma, myeloma & leukemia
Published: December 03, 2025
A nationwide Italian GIMEMA survey on tandem autologous stem cell transplantation for newly diagnosed multiple myeloma patients treated with daratumumab, bortezomib, thalidomide and dexamethasone.
Journal: Haematologica
Published: November 17, 2025
Correction to: Continous or fixed carfilzomib, lenalidomide and dexamethasone (KRD) for relapsed-refractory multiple myeloma: long-term follow-up from a multicenter, retrospective real-life survey from European myeloma network (EMN) Italy : Correction to: annals of hematology.
Journal: Annals of hematology
Published: November 12, 2025
Last Updated: 09/26/2026